We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Countdown to Ionis Pharmaceuticals (IONS) Q3 Earnings: A Look at Estimates Beyond Revenue and EPS
Read MoreHide Full Article
In its upcoming report, Ionis Pharmaceuticals (IONS - Free Report) is predicted by Wall Street analysts to post quarterly loss of $1.17 per share, reflecting a decline of 13.6% compared to the same period last year. Revenues are forecasted to be $128.62 million, representing a year-over-year decrease of 10.7%.
The consensus EPS estimate for the quarter has undergone a downward revision of 2.9% in the past 30 days, bringing it to its present level. This represents how the covering analysts, as a whole, have reassessed their initial estimates during this timeframe.
Prior to a company's earnings announcement, it is crucial to consider revisions to earnings estimates. This serves as a significant indicator for predicting potential investor actions regarding the stock. Empirical research has consistently demonstrated a robust correlation between trends in earnings estimate revision and the short-term price performance of a stock.
While investors usually depend on consensus earnings and revenue estimates to assess the business performance for the quarter, delving into analysts' forecasts for certain key metrics often provides a more comprehensive understanding.
Given this perspective, it's time to examine the average forecasts of specific Ionis Pharmaceuticals metrics that are routinely monitored and predicted by Wall Street analysts.
The consensus estimate for 'Revenue- Commercial Revenue- Licensing and royalty revenue' stands at $5.51 million. The estimate indicates a year-over-year change of -38.8%.
The collective assessment of analysts points to an estimated 'Revenue- Research and development revenue under collaborative agreements' of $49.79 million. The estimate points to a change of -17% from the year-ago quarter.
Analysts expect 'Revenue- Commercial Revenue- Spinraza royalties' to come in at $61.33 million. The estimate indicates a year-over-year change of -8.5%.
Based on the collective assessment of analysts, 'Revenue- Commercial Revenue- Tegsedi and Waylivra revenue, net' should arrive at $7.71 million. The estimate suggests a change of -3.6% year over year.
Analysts' assessment points toward 'Revenue- Total commercial revenue' reaching $79.73 million. The estimate indicates a change of -5.1% from the prior-year quarter.
According to the collective judgment of analysts, 'Revenue- R&D Revenue- Collaborative agreement revenue' should come in at $33.69 million. The estimate points to a change of -23.4% from the year-ago quarter.
Analysts predict that the 'Revenue- R&D Revenue- Amortization from upfront payments' will reach $35.30 million. The estimate suggests a change of +96.1% year over year.
The consensus among analysts is that 'Revenue- R&D Revenue- WAINUA joint development revenue' will reach $15.75 million. The estimate indicates a change of -1.6% from the prior-year quarter.
Over the past month, Ionis Pharmaceuticals shares have recorded returns of +2.2% versus the Zacks S&P 500 composite's +0.4% change. Based on its Zacks Rank #3 (Hold), IONS will likely exhibit a performance that aligns with the overall market in the upcoming period. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Countdown to Ionis Pharmaceuticals (IONS) Q3 Earnings: A Look at Estimates Beyond Revenue and EPS
In its upcoming report, Ionis Pharmaceuticals (IONS - Free Report) is predicted by Wall Street analysts to post quarterly loss of $1.17 per share, reflecting a decline of 13.6% compared to the same period last year. Revenues are forecasted to be $128.62 million, representing a year-over-year decrease of 10.7%.
The consensus EPS estimate for the quarter has undergone a downward revision of 2.9% in the past 30 days, bringing it to its present level. This represents how the covering analysts, as a whole, have reassessed their initial estimates during this timeframe.
Prior to a company's earnings announcement, it is crucial to consider revisions to earnings estimates. This serves as a significant indicator for predicting potential investor actions regarding the stock. Empirical research has consistently demonstrated a robust correlation between trends in earnings estimate revision and the short-term price performance of a stock.
While investors usually depend on consensus earnings and revenue estimates to assess the business performance for the quarter, delving into analysts' forecasts for certain key metrics often provides a more comprehensive understanding.
Given this perspective, it's time to examine the average forecasts of specific Ionis Pharmaceuticals metrics that are routinely monitored and predicted by Wall Street analysts.
The consensus estimate for 'Revenue- Commercial Revenue- Licensing and royalty revenue' stands at $5.51 million. The estimate indicates a year-over-year change of -38.8%.
The collective assessment of analysts points to an estimated 'Revenue- Research and development revenue under collaborative agreements' of $49.79 million. The estimate points to a change of -17% from the year-ago quarter.
Analysts expect 'Revenue- Commercial Revenue- Spinraza royalties' to come in at $61.33 million. The estimate indicates a year-over-year change of -8.5%.
Based on the collective assessment of analysts, 'Revenue- Commercial Revenue- Tegsedi and Waylivra revenue, net' should arrive at $7.71 million. The estimate suggests a change of -3.6% year over year.
Analysts' assessment points toward 'Revenue- Total commercial revenue' reaching $79.73 million. The estimate indicates a change of -5.1% from the prior-year quarter.
According to the collective judgment of analysts, 'Revenue- R&D Revenue- Collaborative agreement revenue' should come in at $33.69 million. The estimate points to a change of -23.4% from the year-ago quarter.
Analysts predict that the 'Revenue- R&D Revenue- Amortization from upfront payments' will reach $35.30 million. The estimate suggests a change of +96.1% year over year.
The consensus among analysts is that 'Revenue- R&D Revenue- WAINUA joint development revenue' will reach $15.75 million. The estimate indicates a change of -1.6% from the prior-year quarter.
View all Key Company Metrics for Ionis Pharmaceuticals here>>>
Over the past month, Ionis Pharmaceuticals shares have recorded returns of +2.2% versus the Zacks S&P 500 composite's +0.4% change. Based on its Zacks Rank #3 (Hold), IONS will likely exhibit a performance that aligns with the overall market in the upcoming period. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>